Estrogen receptor alpha negative breast cancer patients: Estrogen receptor beta as a therapeutic target

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 1-10

  Skliris, George P ^a   Leygue, Etienne ^a   Watson, Peter H ^a   Murphy, Leigh C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Breast cancer; Estrogen receptor negative; Estrogen receptor ; Therapeutic target

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VALIDATION PROCESS; WESTERN BLOTTING;

ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN ISOFORMS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 40849097918     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.12.010     Document Type: Review

References (67)

1. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51 3 (1998) 227-238
2. Osborne C.K., and Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23 8 (2005) 1616-1622
3. Davidson N.E. Biology of breast cancer and its clinical implications. Curr. Opin. Oncol. 4 6 (1992) 1003-1009
4. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, CMAJ 158 (Suppl. 3) (1998) S52-64.
5. Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, CMAJ 158 (Suppl. 3) (1998) S43-51.
6. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8 3 (2007) 235-244
7. Saji S., Omoto Y., Shimizu C., Warner M., Hayashi Y., Horiguchi S., Watanabe T., Hayashi S., Gustafsson J.A., and Toi M. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 62 17 (2002) 4849-4853
8. Chi A., Chen X., Chirala M., and Younes M. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res. 23 1A (2003) 211-216
9. Fuqua S.A., Schiff R., Parra I., Friedrichs W.E., Su J.L., McKee D.D., Slentz-Kesler K., Moore L.B., Willson T.M., and Moore J.T. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 59 21 (1999) 5425-5428
10. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., and Muramatsu M. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res. 26 15 (1998) 3505-3512
11. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol. Endocrinol. 21 1 (2007) 1-13
12. Jarvinen T.A., Pelto-Huikko M., Holli K., and Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 156 1 (2000) 29-35
13. Leygue E., Dotzlaw H., Watson P.H., and Murphy L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 58 15 (1998) 3197-3201
14. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., Warner M., and Gustafsson J.A. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99 24 (2002) 15578-15583
15. Skliris G.P., Munot K., Bell S.M., Carder P.J., Lane S., Horgan K., Lansdown M.R., Parkes A.T., Hanby A.M., Markham A.F., and Speirs V. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 201 2 (2003) 213-220
16. Leygue E., Dotzlaw H., Watson P.H., and Murphy L.C. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 59 6 (1999) 1175-1179
17. Murphy L.C., and Watson P. Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed. Pharmacother. 56 2 (2002) 65-77
18. Murphy L.C., and Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 13 2 (2006) 327-334
19. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., Peterson C., Malmstrom P., Isola J., Borg A., and Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin. Cancer. Res. 13 7 (2007) 1987-1994
20. Dotzlaw H., Leygue E., Watson P.H., and Murphy L.C. Expression of estrogen receptor-beta in human breast tumors. J. Clin. Endocrinol. Metab. 82 7 (1997) 2371-2374
21. Murphy L., Cherlet T., Lewis A., Banu Y., and Watson P. New insights into estrogen receptor function in human breast cancer. Ann. Med. 35 8 (2003) 614-631
22. Skliris G.P., Parkes A.T., Limer J.L., Burdall S.E., Carder P.J., and Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J. Pathol. 197 2 (2002) 155-162
23. Carder P.J., Murphy C.E., Dervan P., Kennedy M., McCann A., Saunders P.T., Shaaban A.M., Foster C.S., Witton C.J., Bartlett J.M., Walker R.A., and Speirs V. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res. Treat. 92 3 (2005) 287-293
24. Weitsman G.E., Skliris G., Ung K., Peng B., Younes M., Watson P.H., and Murphy L.C. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res. Treat. 100 1 (2006) 23-31
25. Adeyinka A., Nui Y., Cherlet T., Snell L., Watson P.H., and Murphy L.C. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 8 6 (2002) 1747-1753
26. Riera J., Simpson J.F., Tamayo R., and Battifora H. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. Am. J. Clin. Pathol. 111 3 (1999) 329-335
27. Poola I., Fuqua S.A., De Witty R.L., Abraham J., Marshallack J.J., and Liu A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin. Cancer Res. 11 20 (2005) 7579-7585
28. Saji S., Hirose M., and Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother. Pharmacol. 56 Suppl. 1 (2005) 21-26
29. Speirs V., Skliris G.P., Burdall S.E., and Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J. Clin. Pathol. 55 5 (2002) 371-374
30. Hopp T.A., Weiss H.L., Parra I.S., Cui Y., Osborne C.K., and Fuqua S.A. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin. Cancer Res. 10 22 (2004) 7490-7499
31. Saunders P.T., Millar M.R., Williams K., Macpherson S., Bayne C., O'Sullivan C., Anderson T.J., Groome N.P., and Miller W.R. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br. J. Cancer 86 2 (2002) 250-256
32. Saunders P.T., Millar M.R., Macpherson S., Irvine D.S., Groome N.P., Evans L.R., Sharpe R.M., and Scobie G.A. ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in distinct cell populations in the adult human testis. J. Clin. Endocrinol. Metab. 87 6 (2002) 2706-2715
33. Murphy L.C., Peng B., Lewis A., Davie J.R., Leygue E., Kemp A., Ung K., Vendetti M., and Shiu R. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J. Mol. Endocrinol. 34 2 (2005) 553-566
34. Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., and Ho S.M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159 1 (2001) 79-92
35. Skliris G.P., Lewis A., Emberley E., Peng B., Weebadda W.K., Kemp A., Davie J.R., Shiu R.P., Watson P.H., and Murphy L.C. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat. (2006)
36. Skliris G.P., Leygue E., Curtis-Snell L., Watson P.H., and Murphy L.C. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br. J. Cancer 95 5 (2006) 616-626
37. Savinov A.Y., Remacle A.G., Golubkov V.S., Krajewska M., Kennedy S., Duffy M.J., Rozanov D.V., Krajewski S., and Strongin A.Y. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res. 66 5 (2006) 2716-2724
38. Jensen E.V., Cheng G., Palmieri C., Saji S., Makela S., Van Noorden S., Wahlstrom T., Warner M., Coombes R.C., and Gustafsson J.A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl. Acad. Sci. USA 98 26 (2001) 15197-15202
39. O'Neill P.A., Davies M.P., Shaaban A.M., Innes H., Torevell A., Sibson D.R., and Foster C.S. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br. J. Cancer 91 9 (2004) 1694-1702
40. Fuqua S.A., Schiff R., Parra I., Moore J.T., Mohsin S.K., Osborne C.K., Clark G.M., and Allred D.C. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 63 10 (2003) 2434-2439
41. Hou Y.F., Yuan S.T., Li H.C., Wu J., Lu J.S., Liu G., Lu L.J., Shen Z.Z., Ding J., and Shao Z.M. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23 34 (2004) 5799-5806
42. Tonetti D.A., Rubenstein R., DeLeon M., Zhao H., Pappas S.G., Bentrem D.J., Chen B., Constantinou A., and Craig Jordan V. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J. Steroid Biochem. Mol. Biol. 87 1 (2003) 47-55
43. Lazennec G., Bresson D., Lucas A., Chauveau C., and Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 9 (2001) 4120-4130
44. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64 1 (2004) 423-428
45. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G.M., and Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95 5 (2003) 353-361
46. Peng B., Lu B., Leygue E., and Murphy L.C. Putative functional characteristics of human estrogen receptor-beta isoforms. J. Mol. Endocrinol. 30 1 (2003) 13-29
47. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61 6 (2001) 2537-2541
48. Saji S., Jensen E.V., Nilsson S., Rylander T., Warner M., and Gustafsson J.A. Estrogen receptors alpha and beta in the rodent mammary gland. Proc. Natl. Acad. Sci. USA 97 1 (2000) 337-342
49. Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes A., Li Y., and Younes M. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 32 1 (2001) 113-118
50. Omoto Y., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., Kobayashi S., and Iwase H. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 163 2 (2001) 207-212
51. Skliris G.P., Carder P.J., Lansdown M.R., and Speirs V. Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?. Br. J. Cancer 84 8 (2001) 1095-1098
52. Murphy L.C., Leygue E., Niu Y., Snell L., Ho S.M., and Watson P.H. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br. J. Cancer 87 12 (2002) 1411-1416
53. Saji S., Omoto Y., Shimizu C., Horiguchi S., Watanabe T., Funata N., Hayash S., Gustafsson J.A., and Toi M. Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer 9 4 (2002) 303-307
54. Omoto Y., Kobayashi S., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., Gustafsson J.A., and Iwase H. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 38 3 (2002) 380-386
55. Iwase H., Zhang Z., Omoto Y., Sugiura H., Yamashita H., Toyama T., Iwata H., and Kobayashi S. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother. Pharmacol. 52 Suppl. 1 (2003) S34-S38
56. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., Gustafsson J.A., and Rochefort H. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. 10 17 (2004) 5769-5776
57. Balfe P., McCann A., McGoldrick A., McAllister K., Kennedy M., Dervan P., and Kerin M.J. Estrogen receptor alpha and beta profiling in human breast cancer. Eur. J. Surg. Oncol. 30 5 (2004) 469-474
58. Myers E., Fleming F.J., Crotty T.B., Kelly G., McDermott E.W., O'Higgins N. J., Hill A.D., and Young L.S. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 91 9 (2004) 1687-1693
59. Palmieri C., Lam E.W., Mansi J., MacDonald C., Shousha S., Madden P., Omoto Y., Sunters A., Warner M., Gustafsson J.A., and Coombes R.C. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin. Cancer Res. 10 7 (2004) 2421-2428
60. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., Giannopoulou I., Givalos N., Markaki S., and Keramopoulos A. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J. Clin. Pathol. 57 5 (2004) 523-528
61. Fleming F.J., Hill A.D., McDermott E.W., O'Higgins N.J., and Young L.S. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J. Clin. Endocrinol. Metab. 89 1 (2004) 375-383
62. Esslimani-Sahla M., Kramar A., Simony-Lafontaine J., Warner M., Gustafsson J.A., and Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin. Cancer Res. 11 9 (2005) 3170-3174
63. Jarzabek K., Koda M., Kozlowski L., Mittre H., Sulkowski S., Kottler M.L., and Wolczynski S. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur. J. Cancer 41 18 (2005) 2924-2934
64. Choi Y., and Pinto M. Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers. Appl. Immunohistochem. Mol. Morphol. 13 1 (2005) 19-24
65. Miller W.R., Anderson T.J., Dixon J.M., and Saunders P.T. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer 94 9 (2006) 1333-1338
66. Umekita Y., Souda M., Ohi Y., Sagara Y., Rai Y., Takahama T., and Yoshida H. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathol. Int. 56 8 (2006) 423-427
67. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., and Slamon D.J. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 18 21 (2000) 3651-3664